{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:39:17Z","timestamp":1792485557709,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T00:00:00Z","timestamp":1785369600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ophtha.2026.07.030","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T11:32:06Z","timestamp":1789471926000},"page":"e149-e167","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biologic Switching Strategies for Anti\u2013Tumor Necrosis Factor Alpha Refractory Noninfectious Uveitis"],"prefix":"10.1016","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6871-6721","authenticated-orcid":false,"given":"Yoo-Ri","family":"Chung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9179-8163","authenticated-orcid":false,"given":"Carmen Ant\u00eda","family":"Rodr\u00edguez-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2860-2340","authenticated-orcid":false,"given":"Ji Hun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-6148","authenticated-orcid":false,"given":"Hae Rang","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji Hyun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bumhee","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7348-7337","authenticated-orcid":false,"given":"Anxo","family":"Fern\u00e1ndez-Ferreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Touhami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Saadoun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahram","family":"Bodaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ophtha.2026.07.030_bib1","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.ophtha.2017.11.017","article-title":"Guidance on noncorticosteroid systemic immunomodulatory therapy in noninfectious uveitis: fundamentals of Care for UveitiS (FOCUS) Initiative","volume":"125","author":"Dick","year":"2018","journal-title":"Ophthalmology"},{"issue":"10050","key":"10.1016\/j.ophtha.2026.07.030_bib2","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/S0140-6736(16)31339-3","article-title":"Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial","volume":"388","author":"Nguyen","year":"2016","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.ophtha.2026.07.030_bib3","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/09273948.2024.2344712","article-title":"Adalimumab for the treatment of non-infectious uveitis: a real life experience","volume":"33","author":"Raad","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"4 Suppl 45","key":"10.1016\/j.ophtha.2026.07.030_bib4","first-page":"S65","article-title":"Infliximab treatment-induced formation of autoantibodies is common in Beh\u00e7et's disease","volume":"25","author":"Elezoglou","year":"2007","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"10.1016\/j.ophtha.2026.07.030_bib5","doi-asserted-by":"crossref","first-page":"2782","DOI":"10.3390\/biomedicines12122782","article-title":"Adalimumab autoantibodies in uveitis patients: do we need routine drug monitoring?","volume":"12","author":"Zur Bonsen","year":"2024","journal-title":"Biomedicines"},{"issue":"2","key":"10.1016\/j.ophtha.2026.07.030_bib6","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1001\/jamaophthalmol.2022.5584","article-title":"Antidrug antibodies to tumor necrosis factor \u03b1 inhibitors in patients with noninfectious uveitis","volume":"141","author":"Bellur","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"10.1016\/j.ophtha.2026.07.030_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2022.851453","article-title":"Tocilizumab and abatacept for the treatment of Childhood Chronic uveitis: a monocentric comparison experience","volume":"10","author":"Maccora","year":"2022","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.ophtha.2026.07.030_bib8","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1080\/09273948.2020.1869787","article-title":"Response to the second TNF-\u03b1 inhibitor (Adalimumab or infliximab) after failing the first one in refractory idiopathic inflammatory retinal vascular leakage","volume":"30","author":"Maleki","year":"2022","journal-title":"Ocul Immunol Inflamm"},{"issue":"11","key":"10.1016\/j.ophtha.2026.07.030_bib9","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.3899\/jrheum.151389","article-title":"Comparable efficacy of abatacept used as first-line or second-line biological agent for severe juvenile idiopathic arthritis-related uveitis","volume":"43","author":"Birolo","year":"2016","journal-title":"J Rheumatol"},{"key":"10.1016\/j.ophtha.2026.07.030_bib10","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2024.100247","article-title":"To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF","volume":"9","author":"Maccora","year":"2024","journal-title":"J Transl Autoimmun"},{"issue":"4","key":"10.1016\/j.ophtha.2026.07.030_bib11","first-page":"652","article-title":"Golimumab in refractory uveitis associated to juvenile idiopathic arthritis: multicentre study of 7 cases and literature review","volume":"36","author":"Palmou-Fontana","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"3 Suppl 72","key":"10.1016\/j.ophtha.2026.07.030_bib12","first-page":"S62","article-title":"Switching of anti-TNF-\u03b1 agents in Beh\u00e7et's disease","volume":"30","author":"Furuta","year":"2012","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.ophtha.2026.07.030_bib13","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/rheumatology\/kem356","article-title":"Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis","volume":"47","author":"Tynj\u00e4l\u00e4","year":"2008","journal-title":"Rheumatology (Oxford)"},{"issue":"Suppl 2","key":"10.1016\/j.ophtha.2026.07.030_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1136\/annrheumdis-2014-eular.4758","article-title":"Golimumab in refractory uveitis to other anti-tnf\u03b1 drugs","volume":"73","author":"Ortiz Sanju\u00e1n","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ophtha.2026.07.030_bib15","first-page":"1146","article-title":"Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey","volume":"34","author":"Foeldvari","year":"2007","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ophtha.2026.07.030_bib16","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10792-016-0239-y","article-title":"Efficacy of golimumab on recurrent uveitis in HLA-B27-positive ankylosing spondylitis","volume":"37","author":"Yazgan","year":"2017","journal-title":"Int Ophthalmol"},{"issue":"8","key":"10.1016\/j.ophtha.2026.07.030_bib17","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1080\/09273948.2023.2263557","article-title":"Successful remission with upadacitinib in two patients with Anti-TNF-Refractory macular edema associated with Beh\u00e7et's uveitis","volume":"32","author":"Tao","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.ophtha.2026.07.030_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ajo.2022.06.024","article-title":"Alternative biologic therapy in children failing conventional TNF\u03b1 inhibitors for refractory, noninfectious, chronic anterior uveitis","volume":"244","author":"Miraldi Utz","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"10.1016\/j.ophtha.2026.07.030_bib19","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1093\/rheumatology\/kex480","article-title":"Anti-interleukin 6 receptor tocilizumab in refractory uveitis associated with Beh\u00e7et's disease: Multicentre retrospective study","volume":"57","author":"Atienza-Mateo","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"7","key":"10.1016\/j.ophtha.2026.07.030_bib20","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/09273948.2017.1355471","article-title":"Tocilizumab for the treatment of Beh\u00e7et Uveitis that failed Interferon alpha and anti-tumor necrosis factor-alpha therapy","volume":"26","author":"Eser Ozturk","year":"2018","journal-title":"Ocul Immunol Inflamm"},{"issue":"4 Suppl 84","key":"10.1016\/j.ophtha.2026.07.030_bib21","first-page":"S75","article-title":"Tocilizumab in severe and refractory non-infectious uveitis","volume":"32","author":"Papo","year":"2014","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.ophtha.2026.07.030_bib22","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/1744666X.2021.1956313","article-title":"Perspectives for immunotherapy in noninfectious immune mediated uveitis","volume":"17","author":"Touhami","year":"2021","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"10.1016\/j.ophtha.2026.07.030_bib23","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12348-025-00529-y","article-title":"Adalimumab in non-infectious uveitis, towards a real-world therapeutic paradigm beyond inflammation control: a multicenter cross-sectional study","volume":"15","author":"Rodr\u00edguez-Fern\u00e1ndez","year":"2025","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"3","key":"10.1016\/j.ophtha.2026.07.030_bib24","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","article-title":"Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders","volume":"121","author":"Levy-Clarke","year":"2014","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2026.07.030_bib25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","article-title":"A review of ocular adverse events of biological anti-TNF drugs","volume":"10","author":"Nicolela Susanna","year":"2020","journal-title":"J Ophthalmic Inflamm Infect"},{"key":"10.1016\/j.ophtha.2026.07.030_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.ajo.2022.02.002","article-title":"Lower relapses rate with Infliximab versus Adalimumab in sight-threatening uveitis: a multicenter Study of 330 patients","volume":"238","author":"Maalouf","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2026.07.030_bib27","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3390\/pharmaceutics15030766","article-title":"Perspectives of therapeutic drug monitoring of biological agents in non-infectious uveitis treatment: a review","volume":"15","author":"Busto-Iglesias","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10271","key":"10.1016\/j.ophtha.2026.07.030_bib28","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S0140-6736(20)32341-2","article-title":"Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid (R4RA): 16 week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomized controlled trial","volume":"397","author":"Humby","year":"2021","journal-title":"Lancet"},{"issue":"22","key":"10.1016\/j.ophtha.2026.07.030_bib29","doi-asserted-by":"crossref","first-page":"5318","DOI":"10.3390\/jcm10225318","article-title":"Primary failure to an Anti-TNF agent in inflammatory bowel disease: switch (to a second Anti-TNF agent) or swap (for another mechanism of action)?","volume":"10","author":"Gisbert","year":"2021","journal-title":"J Clin Med"},{"issue":"6","key":"10.1016\/j.ophtha.2026.07.030_bib30","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1093\/ecco-jcc\/jjy004","article-title":"Primary non-response to tumor necrosis factor antagonists is associated with inferior response to second-line biologics in patients with inflammatory bowel diseases: a systematic review and meta-analysis","volume":"12","author":"Singh","year":"2018","journal-title":"J Crohns Colitis"},{"issue":"1","key":"10.1016\/j.ophtha.2026.07.030_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-75190-x","article-title":"Cycling versus swapping strategies with TNF-\u03b1 inhibitors and IL-17 inhibitors in psoriatic arthritis in clinical practice","volume":"14","author":"Lumetti","year":"2024","journal-title":"Sci Rep"},{"issue":"13","key":"10.1016\/j.ophtha.2026.07.030_bib32","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1167\/iovs.65.13.29","article-title":"Potential prognostic protein biomarkers in tears from noninfectious uveitis patients under biologic treatment as a prelude to personalized medicine","volume":"65","author":"Rodr\u00edguez-Mart\u00ednez","year":"2024","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"10.1016\/j.ophtha.2026.07.030_bib33","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s10067-017-3672-z","article-title":"IL-6 blockade in the management of non-infectious uveitis","volume":"36","author":"Lopalco","year":"2017","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.ophtha.2026.07.030_bib34","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1080\/09273948.2024.2408401","article-title":"Biological and therapeutic role of Interleukin-6 in non-infectious uveitis: a narrative review","volume":"34","author":"Cifuentes-Gonz\u00e1lez","year":"2024","journal-title":"Ocul Immunol Inflamm"},{"issue":"5","key":"10.1016\/j.ophtha.2026.07.030_bib35","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ophtha.2021.11.013","article-title":"Anti-Tumor necrosis factor \u03b1 versus tocilizumab in the treatment of refractory uveitic macular edema: a multicenter Study from the French uveitis network","volume":"129","author":"Leclercq","year":"2022","journal-title":"Ophthalmology"},{"issue":"1","key":"10.1016\/j.ophtha.2026.07.030_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13075-018-1793-7","article-title":"Safety and efficacy of infliximab in the treatment of refractory uveoretinitis in Beh\u00e7et's disease: a large-scale, long-term postmarketing surveillance in Japan","volume":"21","author":"Ohno","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ophtha.2026.07.030_bib37","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.740057","article-title":"TNF-\u03b1 in uveitis: from bench to clinic","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Pharmacol"},{"issue":"Pt 2","key":"10.1016\/j.ophtha.2026.07.030_bib38","article-title":"Interleukin-6 in non-infectious uveitis: biology, experimentalevidence and treatment strategies","volume":"230","author":"Yu","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.ophtha.2026.07.030_bib39","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.3390\/ijms25052789","article-title":"Cellular and molecular determinants of biologic drugs resistance and therapeutic failure in inflammatory bowel disease","volume":"25","author":"Puca","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ophtha.2026.07.030_bib40","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 update of the EULAR recommendations for the management of Beh\u00e7et's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.ophtha.2026.07.030_bib41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4103\/IJO.IJO_61_25","article-title":"JAK-STAT inhibitors in noninfectious uveitis - a review","volume":"73","author":"Pyare","year":"2025","journal-title":"Indian J Ophthalmol"},{"issue":"2","key":"10.1016\/j.ophtha.2026.07.030_bib42","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.semarthrit.2015.05.006","article-title":"Non-anti-TNF biologic modifier drugs in non-infectious refractory chronic uveitis: the current evidence from a systematic review","volume":"45","author":"Simonini","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.ophtha.2026.07.030_bib43","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/jamaophthalmol.2024.2439","article-title":"Filgotinib in active noninfectious uveitis: the HUMBOLDT randomized clinical trial","volume":"142","author":"Srivastava","year":"2024","journal-title":"JAMA Ophthalmol"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202600535X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016164202600535X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T07:56:28Z","timestamp":1792482988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016164202600535X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":43,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S016164202600535X"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.07.030","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biologic Switching Strategies for Anti\u2013Tumor Necrosis Factor Alpha Refractory Noninfectious Uveitis","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2026.07.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Academy of Ophthalmology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}